Adagene Inc.
ADAG evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ADAG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ADAG
Adagene Inc. (ADAG) is a clinical-stage biotechnology company developing antibody-based cancer therapies, with its lead candidate ADG126 (muzastotug) in Phase 1b/2 trials and a pipeline of early-stage wholly-owned and outlicensed programs.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 4 clinical trials for Adagene Inc..
Adagene Inc. (ADAG) is a clinical-stage biotechnology company developing antibody-based cancer therapies, with its lead candidate ADG126 (muzastotug) in Phase 1b/2 trials and a pipeline of early-stage wholly-owned and outlicensed programs.
- Lead product candidate ADG126 (muzastotug) is in Phase 1b/2 clinical development for cancer [sec · filed 2025-03-24].
- Cash and equivalents of $74.5M as of 2025-12-31 [sec].
- Total revenue of $7.7M and net loss of -$17.6M for the period ended 2025-12-31 [sec].
- Shareholders' equity of $50.5M and total debt of $1.8M as of 2025-12-31 [sec].
- Pipeline includes wholly-owned candidates ADG126, ADG116, ADG206, ADG106, and outlicensed candidates ADG104 and ADG125 [sec · filed 2026-04-01].
What works
- Proprietary Dynamic Precision Library platform may enable efficient discovery of antibody product candidates [sec · filed 2025-03-24].
- Lead candidate ADG126 has advanced to Phase 1b/2, indicating some clinical progress [sec · filed 2025-03-24].
- Modest debt of $1.8M relative to equity suggests low leverage [sec].
What to weigh
- All wholly-owned product candidates are in early stages of development and require significant further investment [sec · filed 2026-04-01].
- Company has incurred net losses historically and expects to continue incurring losses before any product commercialization [sec · filed 2025-03-24].
- Substantial additional financing may be needed, which may not be available on acceptable terms [sec · filed 2026-04-01].
- Success depends heavily on ADG126; failure of this candidate would materially harm the business [sec · filed 2025-03-24].
From the filings
Quoted directly from source documents.
Lead candidate ADG126 is in Phase 1b/2 clinical development.
“particularly our lead product candidate, ADG126, which is in phase 1b/2 clinical development”
SEC filings · March 24, 2025
Company has incurred net losses historically.
“We have incurred net losses historica”
SEC filings · April 1, 2026
All product candidates are in early stages and require significant further development.
“our current product candidates are in relatively early stages of development. We have invested a significant portion of our efforts and financial resources in the development of our existing product candidates and all of our product candidates will require significant further development and financial resources.”
SEC filings · April 1, 2026
Substantial additional financing may be needed.
“We may need to obtain substantial additional financing to fund our growth and operations, which may not be available on acceptable terms, if at all.”
SEC filings · April 1, 2026
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Clinical trials of product candidates may not be successful, materially harming business [sec · filed 2025-03-24].
- Dependence on lead candidate — Business depends substantially on success of ADG126; failure would be material [sec · filed 2025-03-24].
- Need for additional capital — Substantial additional financing may be required and may not be available on acceptable terms [sec · filed 2026-04-01].
- Early-stage pipeline — All wholly-owned candidates are in early development; no approved products or revenue from product sales [sec · filed 2026-04-01].
What to watch
- Enrollment and data readouts from Phase 1b/2 trial of ADG126 [sec · filed 2025-03-24].
- Any updates on regulatory interactions with FDA or NMPA for ADG126 or other candidates [sec · filed 2026-04-01].
- Cash runway and potential need for additional financing given $74.5M cash and ongoing losses [sec].
- Progress of earlier-stage candidates ADG116, ADG206, ADG106 through preclinical and clinical stages [sec · filed 2026-04-01].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Adagene Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Adagene Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
14.4 months
D/E 0.75 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$3.4M
| Holder | Shares | Value |
|---|---|---|
| ameriprise financial inc | 607,903 | $2.4M |
| morgan stanley | 66,148 | $259K |
| smartharvest portfolios, llc | 40,312 | $158K |
| renaissance technologies llc | 34,533 | $135K |
| jane street group, llc | 30,425 | $119K |
| alyeska investment group, l.p. | 20,710 | $81K |
| royal bank of canada | 16,850 | $66K |
| nomura holdings inc | 14,710 | $58K |
| quadrature capital ltd | 11,617 | $46K |
| geode capital management, llc | 10,309 | $40K |
Showing top 10 of 18 institutional holders of Adagene Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 0.2%
- Days to cover
- 0.3
- Shares short
- 71,244
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ADAG short interestFrequently asked questions
What is the AI investment thesis for Adagene Inc.?
Adagene Inc. (ADAG) is a clinical-stage biotechnology company developing antibody-based cancer therapies, with its lead candidate ADG126 (muzastotug) in Phase 1b/2 trials and a pipeline of early-stage wholly-owned and outlicensed programs.
Who is the CEO of Adagene Inc.?
Dr. Peter P. Luo Ph.D. is the chief executive officer of Adagene Inc. (ADAG).
Where is Adagene Inc. headquartered?
Adagene Inc. (ADAG) is headquartered in Suzhou, China.
What therapeutic areas does Adagene Inc. focus on?
Adagene Inc. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.